UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 44

Sortiert nach

Aggressive estrogen-receptor-positive breast cancer arising in patients with elevated body mass index

International journal of clinical oncology, 2015-04, Vol.20 (2), p.317-323

2015

Link zum Volltext

Verfügbarkeit prüfen

Management of Metastatic HER2-Positive Breast Cancer: Where Are We and Where Do We Go From Here?

Oncology (Williston Park, N.Y.), 2016-02, Vol.30 (2), p.148-155

2016

Link zum Volltext

Verfügbarkeit prüfen

Manganese Superoxide Dismutase Acetylation and Dysregulation, Due to Loss of SIRT3 Activity, Promote a Luminal B-Like Breast Carcinogenic-Permissive Phenotype

Antioxidants & redox signaling, 2016-08, Vol.25 (6), p.326

2016

Link zum Volltext

Verfügbarkeit prüfen

Patient-reported Outcomes of Patients With Breast Cancer During the COVID-19 Outbreak in the Epicenter of China: A Cross-sectional Survey Study

Clinical breast cancer, 2020-10, Vol.20 (5), p.e651-e662

2020

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant Therapy for Early-Stage Breast Cancer: Current Practice, Controversies, and Future Directions

Oncology (Williston Park, N.Y.), 2015-11, Vol.29 (11), p.828-838

2015

Link zum Volltext

Verfügbarkeit prüfen

Obese Breast Cancer Patients and Survivors: Management Considerations

Oncology (Williston Park, N.Y.), 2018-08, Vol.32 (8), p.410-417

2018

Link zum Volltext

Verfügbarkeit prüfen

The Role of Ovarian Suppression in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer

Oncology (Williston Park, N.Y.), 2015-07, Vol.29 (7), p.473-481

2015

Link zum Volltext

Verfügbarkeit prüfen

ASCENT-05/OptimICE-RD (AFT-65): Phase 3, randomized, open-label study of adjuvant sacituzumab govitecan (SG) + pembrolizumab (pembro) vs pembro ± capecitabine (cape) in patients (pts) with triple-negative breast cancer (TNBC) and residual disease after neoadjuvant therapy (NAT) and surgery

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS619-TPS619

2023

Link zum Volltext

Verfügbarkeit prüfen

Circulating tumor cells in patients with hormone receptor-positive, HER2-negative metastatic breast cancer receiving palbociclib with fulvestrant after progression on palbociclib with an aromatase inhibitor

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e13018-e13018

2023

Link zum Volltext

Verfügbarkeit prüfen

OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer

Future oncology (London, England), 2024-06, p.1

2024

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of alpelisib (BYL-719) and T-DM1 in HER2-positive metastatic breast cancer after trastuzumab and taxane therapy

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.1026-1026

2017

Link zum Volltext

Verfügbarkeit prüfen

Rationale and design of phase 1 FTIH study of FOXP3 antisense oligonucleotide AZD8701 in patients with selected advanced solid tumors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS3166-TPS3166

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract S07-02: Patient-reported outcomes of breast cancer patients during the COVID-19 outbreak in the epicenter of China: A cross-sectional survey study

Clinical cancer research, 2020-09, Vol.26 (18_Supplement), p.S07-S07-02

2020

Link zum Volltext

Verfügbarkeit prüfen

The impact of weight loss on physical function in overweight or obese breast cancer survivors

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.12053-12053

2020

Link zum Volltext

Verfügbarkeit prüfen

A phase II trial of atezolizumab (anti-PD-L1) with carboplatin in patients with metastatic triple-negative breast cancer (mTNBC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS1112-TPS1112

2020

Link zum Volltext

Verfügbarkeit prüfen

Anti-PD-1 for patients with leptomeningeal metastasis from advanced solid tumors: Efficacy, safety, and biomarkers of response

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e14506-e14506

2020

Link zum Volltext

Verfügbarkeit prüfen

A pilot study of palbociclib in patients with HER2-positive breast cancer with brain metastasis

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS1110-TPS1110

2017

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of pembrolizumab and capecitabine for triple-negative (TN) and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer (MBC)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.1096-1096

2019

Link zum Volltext

Verfügbarkeit prüfen

TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.1002-1002

2020

Link zum Volltext

Verfügbarkeit prüfen

Relationship of pathological features and a 21 gene expression assay in young women with early breast cancer

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e12050-e12050

2017

Link zum Volltext

Verfügbarkeit prüfen

A pilot phase II trial of cabergoline in the treatment of metastatic breast cancer

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e12568-e12568

2017

Link zum Volltext

Verfügbarkeit prüfen

Does the innovative 4R Cancer Care Delivery Model improve patient self-management in safety net and non-safety net centers?

Journal of clinical oncology, 2019-09, Vol.37 (27_suppl), p.172-172

2019

Link zum Volltext

Verfügbarkeit prüfen

Does the innovative 4R Care Delivery Model improve timing and sequencing of guideline recommended breast cancer care in safety net and non-safety net centers?

Journal of clinical oncology, 2019-09, Vol.37 (27_suppl), p.36-36

2019

Link zum Volltext

Verfügbarkeit prüfen

Circulating tumor cells enumeration (CTCs) and circulating tumor DNA (ctDNA): Clinical and molecular features of “rapidly progressing” stage IV disease (Stage IV prog )

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.12040-12040

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 44

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(44)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(44)

Sprache

Englisch
(41)
Portugiesisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Aggressive estrogen-receptor-positive breast cancer arising in patients with elevated body mass index

Management of Metastatic HER2-Positive Breast Cancer: Where Are We and Where Do We Go From Here?

Manganese Superoxide Dismutase Acetylation and Dysregulation, Due to Loss of SIRT3 Activity, Promote a Luminal B-Like Breast Carcinogenic-Permissive Phenotype

Patient-reported Outcomes of Patients With Breast Cancer During the COVID-19 Outbreak in the Epicenter of China: A Cross-sectional Survey Study

Neoadjuvant Therapy for Early-Stage Breast Cancer: Current Practice, Controversies, and Future Directions

Obese Breast Cancer Patients and Survivors: Management Considerations

The Role of Ovarian Suppression in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer

ASCENT-05/OptimICE-RD (AFT-65): Phase 3, randomized, open-label study of adjuvant sacituzumab govitecan (SG) + pembrolizumab (pembro) vs pembro ± capecitabine (cape) in patients (pts) with triple-negative breast cancer (TNBC) and residual disease after neoadjuvant therapy (NAT) and surgery

Circulating tumor cells in patients with hormone receptor-positive, HER2-negative metastatic breast cancer receiving palbociclib with fulvestrant after progression on palbociclib with an aromatase inhibitor

OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer

Phase I study of alpelisib (BYL-719) and T-DM1 in HER2-positive metastatic breast cancer after trastuzumab and taxane therapy

Rationale and design of phase 1 FTIH study of FOXP3 antisense oligonucleotide AZD8701 in patients with selected advanced solid tumors

Abstract S07-02: Patient-reported outcomes of breast cancer patients during the COVID-19 outbreak in the epicenter of China: A cross-sectional survey study

The impact of weight loss on physical function in overweight or obese breast cancer survivors

A phase II trial of atezolizumab (anti-PD-L1) with carboplatin in patients with metastatic triple-negative breast cancer (mTNBC)

Anti-PD-1 for patients with leptomeningeal metastasis from advanced solid tumors: Efficacy, safety, and biomarkers of response

A pilot study of palbociclib in patients with HER2-positive breast cancer with brain metastasis

A phase II study of pembrolizumab and capecitabine for triple-negative (TN) and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer (MBC)

TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded)

Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer

Relationship of pathological features and a 21 gene expression assay in young women with early breast cancer

A pilot phase II trial of cabergoline in the treatment of metastatic breast cancer

Does the innovative 4R Cancer Care Delivery Model improve patient self-management in safety net and non-safety net centers?

Does the innovative 4R Care Delivery Model improve timing and sequencing of guideline recommended breast cancer care in safety net and non-safety net centers?

Circulating tumor cells enumeration (CTCs) and circulating tumor DNA (ctDNA): Clinical and molecular features of “rapidly progressing” stage IV disease (Stage IV prog )

Suchergebnisse filtern